Abstract 111P
Background
About one-third of newly diagnosed NSCLC was stage III unresectable and resectable patients (pts). Stage III NSCLC have high heterogeneity. Currently, real-world molecular testing pattern, treatment pattern and the associated survival outcomes are limited.
Methods
This prospective real-world study enrolled untreated stage III NSCLC pts from 28 hospitals in China. Unresectable and resectable pts were studied separately in cohort 1(C1) and cohort 2(C2). The primary endpoint was treatment pattern of C1, secondary endpoints included molecular testing pattern, progression-free survival (PFS), overall survival (OS) of C1 and treatment pattern of C2.
Results
From 2019 July to 2022 February, 486 pts were included, with 379 pts in C1 and 107 pts in C2. Median age was 63 years (range: 25-85), 82.9% were male. The testing/positive rates of EGFR, ALK, and PD-L1 (≥1%) were 20.0%/39.2%, 15.0%/23.3%, and 13.0%/73.0%, respectively. In C1, 201 (53.0%) pts received radiotherapy (RT), among whom 86.1% (173/201) were chemoradiotherapy (CRT), including 63.6% (110/173) concurrent CRT (cCRT) and 36.4% (63/173) sequential CRT (sCRT). Following CRT, 53.8% pts received consolidation therapy, among whom 58.1 % were immunotherapy-based (IO-based) therapy, of with 35.2% were durvalumab-based therapy. For pts without RT, chemotherapy only or chemotherapy plus anti-angiogenesis therapy, was most commonly used (60.1% [107/178]), followed by chemoimmunotherapy (27.0% [48/178]). In C2, 61.9% had neo-adjuvant treatment, with chemotherapy alone (40.0%) or combined with IO (40%) as the main regimens. Adjuvant treatment was planned for 71.4% pts. As of April 30, 2024 (data cut-off), for pts in C1, the overall median PFS (mPFS) and median OS (mOS) were 12.6 months (95% CI, 11.0-14.0) and 33.3 months (95% CI, 29.6-NE), respectively. For pts in C1 treated with CRT followed by IO-based consolidation therapy, mPFS and mOS were 15.1 months (95% CI, 12.7-28.5) and NE (95% CI, 30.5-NE), respectively. The 2-yr OS rate was 82.6% (95%CI, 69.2-90.6).
Conclusions
MOOREA study presents real-world testing and treatment patterns in stage III NSCLC and showed the effectiveness of CRT followed by IO-base consolidation therapy in this setting.
Clinical trial identification
NCT04023812.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract